Moclobemide attenuates anoxia and glutamate induced neuronal damage in vitro independently of interaction with glutamate receptors subtypes

Brain Research, 1138:30-38


Biocodex, Département de Pharmacologie, Zac de Mercières-Chemin d’Armancourt, 60200 Compiègne, France.
Bioalternatives, Gençay, France.


Recent data suggested the existence of a bidirectional relation between depression and neurodegenerative diseases resulting from cerebral ischemia injury. Glutamate, a major excitatory neurotransmitter, has long been recognised to play a key role in the pathophysiology of anoxia or ischemia, due to its excessive accumulation in the extracellular space and the subsequent activation of its receptors. A characteristic response to glutamate is the increase in cytosolic Na(+) and Ca(2+) levels which is due mainly to influx from the extracellular space, with a consequent cell swelling and oxidative metabolism dysfunction.
The present study examined the in vitro effects of the antidepressant and type-A monoamine oxidase inhibitor, moclobemide, in neuronal-astroglial cultures from rat cerebral cortex exposed to anoxia (for 5 and 7 h) or to glutamate (2 mM for 6 h), two in vitro models of brain ischemia. In addition, the affinity of moclobemide for the different glutamate receptor subtypes and an interaction with the cell influx of Na(+) and of Ca(2+) enhanced by veratridine and K(+) excess, respectively, were evaluated. Moclobemide (10-100 microM) included in the culture medium during anoxia or with glutamate significantly increased in a concentration-dependent manner the amount of surviving neurons compared to controls. Moclobemide displayed no binding affinity for the different glutamate receptor subtypes (IC(50)>100 microM) and did not block up to 300 microM the entry of Na(+) and of Ca(2+) activated by veratridine and K(+), respectively.
These results suggest that the neuroprotective properties of moclobemide imply neither the glutamate neurotransmission nor the Na(+) and Ca(2+) channels.

© 2007 Elsevier B.V.

KEYWORDS: Moclobemide; Anoxia; L-Glutamate; Neuronal–astroglial culture; Neuroprotection; Rat

Check out Bioalternatives’ updates and experience new testing ideas

  • Bioassays, models and services
  • Posts and publications
  • Events
  • The legal basis for the processing is consent. Your e-mail address will only be communicated to the following recipients: the departments concerned and authorised by QIMA LIFE SCIENCE. This data is kept for as long as you are registered to the newsletter.

    You can access your data, rectify it, request its deletion or exercise your right to limit the processing of your data, withdraw your consent to the processing of your data at any time, oppose the processing of your data and you have a right to the portability of your data.

    Visit for more information on your rights.
    You can exercise all your rights using the following linkGestion des droits or by writing to If you feel, after contacting us, that your "Informatique et Libertés" rights are not being respected, you can submit a complaint to the CNIL.

  • The information collected on this form is recorded in a file used by QIMA Life Sciences to send you its newsletter.